ST. LOUIS, March 05, 2025--(BUSINESS WIRE)--Cofactor Genomics announced today OncoPrism for colorectal, breast, bladder, and kidney cancer. This announcement follows recent Medicare coverage of the ...
Cofactor Genomics Announces Strategic Investment by Labcorp and Ascension Ventures to Fuel Expansion of Its OncoPrism® Immunotherapy Diagnostic Across U.S. Cancer Care Networks Cofactor Genomics, a ...
Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback